The UK's National Health Service has introduced a new injection for cancer treatment, allowing thousands of patients to reduce their hospital treatment time. The new treatment, known as Keytruda, is an injectable form of an immune drug that helps the body's immune system fight cancer cells.
Since 2015, patients have received this drug through intravenous injection, a procedure that takes over an hour. However, with the new form, this time can be cut down to just a few minutes, saving valuable time for both patients and medical staff.
Details of the Event
The new injection was trialed at the Mount Vernon Cancer Centre near Watford, where Shirley Zierks, an 86-year-old woman, was among the first to receive the injection. She expressed her happiness with the time saved by the injection, stating, "I spent just a few minutes in the chair instead of an hour or more."
Approximately 14,000 cancer patients in England begin their treatment with Keytruda each year, and most are expected to transition to the injectable version. This drug can be used to treat 14 different types of cancer in the UK, including lung cancer, head and neck cancer, cervical cancer, and breast cancer.
Background & Context
Keytruda is one of the first approved immune drugs, initially used to treat skin cancer before its application was expanded to include other types of cancer. The discoveries made by scientists in this field earned them the Nobel Prize in Medicine in 2018, contributing to the understanding of how immunity works against cancer.
Until now, medical teams in hospitals have had to prepare the drug in sterile conditions, which increases the time spent on treatment. With the introduction of the new injection, experts hope to improve the patient experience and alleviate pressure on chemotherapy units.
Impact & Consequences
The shift to the rapid injection is a significant step towards enhancing cancer patient care. Professor Peter Johnson, the national clinical director for cancer at the NHS, stated that "managing cancer treatment and regular hospital visits can be extremely stressful." He added that reducing treatment time will open up opportunities for providing treatment in the community rather than in hospitals.
However, questions remain regarding the cost of the new treatment, as the NHS has not disclosed details of the deal with Merck Sharp & Dohme, but it is understood that they will pay the same price for both forms of the drug.
Regional Significance
These developments in cancer treatment are significant for the Arab region, where many countries suffer from high cancer incidence rates. Innovations like Keytruda can contribute to improving access to modern treatments, enhancing the chances of recovery for patients in Arab countries.
In conclusion, the introduction of the new injection represents a positive step towards improving cancer patient care, providing them with time and comfort, and enhancing the healthcare system's ability to deliver better services.